替吉奥抗癌治疗的临床研究进展

Clinical research progress of gimeracil and oteracil porassium in anticarcinogen

替吉奥是一种氟尿嘧啶衍生物,为口服抗癌剂。它包括主体成分替加氟及以下两类生化调节剂:吉美嘧啶和奥替拉西,它们是氟尿嘧啶的增效减毒改良制剂。目前已作为治疗胃癌、食管癌、头颈部癌、结直肠癌和多种晚期转移癌的一线治疗药物,并与铂类等抗肿瘤药物联合应用治疗多种癌症有显著疗效,但具体针对某些肿瘤如胰腺癌、胆道肿瘤、乳腺癌、肝细胞癌等的治疗方案目前尚不明确,需研究并进一步完善。本文综述替吉奥对胰腺癌、胆道肿瘤、乳腺癌、肝细胞癌的治疗研究进展。

Gimeracil and oteracil porassium is a oral anticarcinogen derived from fluorouracil （5- Fu）. Gimeracil and oteracil porassium includes tegafur and two biochemical conditioning agents that are gimeracil and oteracil.It＇ s a effect-enhancing and toxicity-reducing improved preparation of 5- Fu. At present, it serves as one of first-line treatment drugs for gastric cancer, esophagus cancer, head-neck carcinoma, colorectal cancer, avariety of advanced metastatic carcinoma and so on. Not only that, it has a significant effect for curing various types of cancer when it combines with platinum. Even so, the effects of therapeutic schedule include gimeracil and oteracil porassium for some cancers, such as pancreatic cancer, biliary tract cancer, breast cancer, and hepatocellular carcinoma, are not clear. The therapeutic schedule need more clinical trials to perfect. This research summarizes the latest treatments included gimeracil and oteracil porassium for anticancer of pancreatic cancer, biliary tract cancer, breast cancer, and hepatocellular carcinoma.